Immune to Cancer: The CRI Blog
-
A Run to Reach New Heights
Earlier this month, Team CRI runners ran the 2015 United Airlines Half Marathon in NYC.
-
Whose Cancer Is It, Anyway?
When navigating cancer with someone you love, does the experience belong to just one of you?
-
Merck’s PD-1 Drug Outperforms Ipilimumab for Treatment of Advanced Melanoma
Data from a phase III trial indicate that Keytruda stands ready to become standard-of-care for advanced melanoma.
-
Longboarding in the Fight Against Cancer with James McGary
Professional longboarder James is going the distance: he's longboarding from Seattle to New York City to raise…
-
Pam G’s Immunotherapy Story
Lung Cancer | Diagnosed 2013 I would not be alive today if it were not for this… -
CRI Scientists Honored With Five AACR Awards
Carl June, Elizabeth Jaffee, James Allison, David Baltimore, and Owen Witte pick up prestigious cancer awards.
-
What Cancer Patients Need to Know About the Opdivo Approval
Now that Opdivo (nivolumab) has been FDA approved for two cancer types, many patients are wondering: what’s…
-
CRI’s James Allison, Arming the Immune System
The director of CRI's Scientific Advisory Council talks immunotherapy with the New York Times.
-
Big News: FDA Approves Opdivo (Nivolumab) for Lung Cancer
The PD-1 checkpoint inhibitor Opdivo® (nivolumab) is a new treatment option for patients with non-small cell lung…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.